

Combined Effect of Maternal Obesity and Diabetes on Excessive Fetal Growth: Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 2012–2015



Sixtus Aguree, PhD,^{1,2} Xiaofei Zhang, PhD,³ Manju B. Reddy, PhD¹

Introduction: Obesity and dysregulation in glucose metabolism are risk factors for excessive fetal growth, but their combined effects are not often examined in a single study.

Methods: Data from the Centers for Disease Control and Prevention's Pregnancy Risk Assessment Monitoring System Phase 7 (2012–2015) were used. Logistic regression was used to investigate the association between maternal prepregnancy BMI and pre-existing diabetes/gestational diabetes on the odds of delivering a large-for-gestational-age infant or an infant with macrosomia.

Results: Complete data for 128,199 singleton births were used. The proportions of large-for-gestational-age infants and infants with macrosomia increased with the degree of obesity ($p < 0.001$) and were higher in women with diabetes than in those without ($p < 0.001$). Compared with the AOR among normal-weight women, the AOR of delivering large-for-gestational-age infants and infants with macrosomia among women with morbid obesity ($BMI \geq 40$) were 2.82 ($p < 0.001$) and 2.67 ($p < 0.001$), respectively. Compared with the AOR among nondiabetic women, the AOR of delivering a large-for-gestational-age infant was 1.88 ($p < 0.001$) among those with pre-existing diabetes and 1.49 ($p < 0.001$) among those with gestational diabetes. Except for the underweight group, women with pre-existing diabetes were nearly twice as likely to deliver a large-for-gestational-age infant as those with similar BMI without diabetes. Women with morbid obesity and gestational diabetes were twice as likely to have a large-for-gestational-age infant and an infant with macrosomia as nondiabetic women with normal BMI.

Conclusions: We have shown that when maternal obesity and diabetes, particularly pre-existing diabetes, occur together, the risk of delivering large-for-gestational-age and macrosomia increases significantly. Our findings call for public health attention to address maternal obesity and diabetes to minimize suboptimal fetal growth.

AJPM Focus 2023;2(2):100071. Published by Elsevier Inc. on behalf of The American Journal of Preventive Medicine Board of Governors. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

INTRODUCTION

The rise in obesity over the last 3 decades has contributed to many health complications at the individual level, burdening many countries' health systems and economies. The latest data from the Centers for

From the ¹Department of Food Science and Human Nutrition, Iowa State University, Ames, Iowa; ²Department of Applied Health Science, Indiana University School of Public Health, Bloomington, Indiana; and ³Department of Statistics, Iowa State University, Ames, Iowa

Address correspondence to: Manju B. Reddy, PhD, Department of Food Science and Human Nutrition, Iowa State University, 2302 Osborn Drive, 220 MacKay, Ames IA 50011. E-mail: mbreddy@iastate.edu.

2773-0654/\$36.00

<https://doi.org/10.1016/j.focus.2023.100071>

Disease Control and Prevention (CDC) shows that >4 in 10 adults aged ≥ 20 years in the U.S. are obese (42%).¹ Furthermore, it has been predicted that by the year 2030, nearly 1 in 2 adults will have obesity (49%), with severe obesity projected to become the most common BMI category among women (28%).² Numerous studies have reported strong associations between maternal obesity and other chronic diseases such as hypertension, cancers, cardiovascular diseases, and diabetes.^{3–5} For instance, the risk of developing gestational diabetes is 9 times higher in women who are obese than in normal-weight women of similar age.⁶ Obesity, when it occurs together with pre-existing diabetes or gestational diabetes, increases the risk for cesarean section and maternal morbidity.^{7–9} In addition, women with gestational diabetes are at a higher risk of recurrence of gestational diabetes and developing Type 2 diabetes later in life.^{10,11}

Furthermore, obesity increases the risk of impaired glucose metabolism during pregnancy, causing excessive fetal growth, including large for gestational age (LGA) and macrosomia.^{12–14} LGA is defined as birthweights greater than the 90th percentile birth weight for their gestational age, race, and fetal sex, and CDC Pregnancy Risk Assessment Monitoring System (PRAMS) classified infants as macrosomic if their birth weight was >4,500 g.¹⁵ Macrosomia is commonly defined as birth >4,000 g or 4,500 g.^{15,16} LGA and macrosomia increase the risk for infant shoulder dystocia, clavicle fractures, and death.^{17–20} Infants with macrosomia are also more likely to become children with overweight/obesity^{17,18,21} and to have large babies later in life.^{6,17}

Although most studies often focus on the individual relationship, such as obesity and LGA or macrosomia or gestational diabetes and macrosomia,^{22,23} data on the combined effect of obesity and diabetes on LGA and macrosomia are limited. Thus, few studies have simultaneously compared the independent and additive impact of obesity and diabetes on the risk of delivering an LGA infant or an infant with macrosomia. Furthermore, most studies often involved fewer participants and focused on gestational diabetes, not pre-existing diabetes. Because pre-existing diabetes and gestational diabetes could have different effects on clinical comorbidities such as chronic hypertension, pre-eclampsia, delivery-related risks, and birth weight,^{14,22,24–26} it is important to examine how both conditions contribute to the risk of LGA and macrosomia. This study aimed to evaluate the independent and combined effect of prepregnancy obesity and diabetes on the risk of LGA and macrosomia among singleton live births in the U.S.

METHODS

Study Population

We used data obtained from CDC's PRAMS, a survey designed to evaluate the maternal health of U.S. women and infants. Specifically, we used PRAMS Phase 7 (2012–2015) data with analysis restricted to singleton live births. Related questions from PRAMS Phase 7 are available from the CDC website,²⁷ and detailed methodology for PRAMS study design is reported elsewhere.^{28,29} Using standardized data collection methodology across states, PRAMS data collection is conducted by state, territorial, tribal, or local health departments in partnership with CDC's Division of Reproductive Health. Birth certificate records are used in each participating jurisdiction to select a representative sample of all women who delivered a live-born infant. Annual state sample sizes range from approximately 1,000 to 3,000 women. Each participating state collects state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. The PRAMS methodology and protocol are reviewed and approved by CDC IRB.²⁹ The primary outcome of this study was the risk of delivering an LGA infant or an infant with macrosomia given maternal BMI and diabetes status.

Measures

We examined CDC PRAMS data explicitly focusing on maternal sociodemographic and health information before and during pregnancy and after delivery. Specifically, maternal prepregnancy BMI, pre-existing diabetes, gestational diabetes, and birthweight of the infants were examined. Infants with birthweights greater than the 90th percentile were classified as LGA. Birthweight >4,000 g was classified as macrosomic.

The analysis included the mother's age (<25, 25–29, 30–34, 35–39, and 40+ years), parity (0, 1, or 2+), newborn sex, race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, other [Asian, American Indian/Alaska Native, Pacific Islander, or multiple]), mother's education (<12, 12, or >12 years), marital status (married or not married), initiation of prenatal care (first trimester, after the first trimester [late], or not at all), and the number of prenatal care visits and gestational weight gain in the most recent pregnancy. Subjects were characterized by maternal prepregnancy BMI, divided into underweight (BMI < 18.5 kg/m²), normal (BMI = 18.5–24.9 kg/m²), overweight (BMI = 25.0–29.9 kg/m²), and obese (obese Class I, BMI = 30.0–34.9 kg/m²; obese Class II, BMI = 35.0–39.9 kg/m²; and obese Class III, BMI ≥ 40 kg/m²).^{30,31} Pre-existing diabetes was defined as diabetes

reported before the recent pregnancy, whereas gestational diabetes occurred only during the pregnancy.

Statistical Analysis

Descriptive characteristics for infants and mothers are presented as frequencies (unweighted) and weighted percentages (% [SE]) for categorical variables and (mean [SE]) for continuous variables. A chi-square test of independence was performed to determine whether there was a significant association between maternal or infant characteristics with BMI status or birth outcomes (LGA versus non-LGA and macrosomic versus nonmacrosomic infants). Weighted logistic regression models were fitted to examine the relationships between maternal BMI and diabetes and the odds of delivering an LGA infant or an infant with macrosomia. The results were expressed as ORs and AORs with corresponding 95% CIs. The weighted logistic regressions adjusted for maternal age, race/ethnicity, mother's education, marital status, parity, prenatal care (initiation and the number of prenatal care visits), health insurance, gestational weight gain, and newborn sex. Interaction terms between diabetes status and LGA (and macrosomia) were included in the respective models. Statistical analyses were performed with Stata (Version 14; Stata Corp., College Station, TX) with sample weights and design variables to account for the complex sample design. Statistical comparisons were evaluated at a 2-sided significance level, and $\alpha=0.05$ was considered statistically significant.

RESULTS

The total data consisted of 147,747 subjects, where 6,689 subjects had missing records for BMI. Among the 141,058 participants with BMI records, we selected subjects with nonmissing records for diabetes status, LGA, macrosomia, and singleton live births data for the analysis ($n=128,199$, i.e., weighted $n=6,690,013$). The mean (SD) for BMI for underweight, normal weight, overweight, and obese (Classes I, II, and III) were 17.5 (0.9), 22.0 (1.7), 27.2 (1.4), 32.2 (1.4), 37.2 (1.4), and 44.9 (4.8), respectively. The proportion of participants in underweight, normal weight, overweight, and obese (Classes I, II, and III) categories were respectively 4.0%, 49.1%, 24.4%, 12.4%, 6.0%, and 4.1%. The proportions of women that reported pre-existing and gestational diabetes were 2.2% and 5.5%, respectively (data not shown). Demographic data and clinical information for the study population are presented in [Table 1](#). BMI was strongly associated with women's age ($p<0.001$), race/ethnicity ($p<0.001$), education ($p<0.001$), marital status ($p<0.001$), parity ($p<0.001$), and prenatal care (number

of prenatal care visits [$p<0.001$]), health insurance at delivery ($p<0.001$), and gestational weight gain ($p<0.001$). Diabetes status (both pre-existing and gestational diabetes) was also associated with BMI ($p<0.001$) ([Table 1](#)).

[Table 2](#) shows the frequencies of LGA or macrosomia in newborn infants by maternal and infant characteristics. First, we looked at the single effect of the degree of obesity and diabetes status on LGA or macrosomic infant delivery. The proportions of newborns classified as LGA and macrosomic are 10.0% and 8.9%, respectively. If the cut off for classifying macrosomia were changed from 4,000 g to 4,500 g, the proportion of infants with macrosomia would be much smaller at 1.2% ([Appendix Table 1](#), available online, for details). Both LGA and macrosomia have a statistically significant relationship ($p<0.001$) with maternal age, BMI, parity, and the total number of prenatal care visits. The proportion of women delivering an LGA infant and an infant with macrosomia increased with the degree of obesity ($p<0.001$). The weighted prevalence of LGA and macrosomia by BMI class and diabetes status are presented in [Table 3](#). The prevalence of newborns classified as LGA increased from 3.6% (underweight), 7.5% (normal weight), 13.6% (obese Class I), to 16.9% (obese Class III). The prevalence of newborns classified as macrosomic increased from 3.1% (underweight), 7.3% (normal weight), 11.3% (obese Class I), to 13.5% in obese Class III. Women with pre-existing diabetes are at an elevated risk for delivering LGA (19.9% vs 9.3%, $p<0.001$) and macrosomic (12.6% vs 8.6%, $p<0.001$) infants compared with women without diabetes. Similarly, women with gestational diabetes showed higher risks for LGA (17.6% vs 9.3%, $p<0.001$) and macrosomia (12.2% vs 8.6%, $p<0.001$) than women without diabetes. Thus, an increase in BMI and the presence of either pre-existing or gestational diabetes results in a significantly increased risk for LGA and macrosomia.

Next, we calculated the odds of delivering an LGA infant or an infant with macrosomia by the degree of obesity and diabetes status, adjusting for demographic and prenatal care factors influencing birthweight ([Table 4](#)). Overall, the odds (AOR) of delivering an LGA infant or an infant with macrosomia increased with the degree of obesity. Compared with that of normal-weight mothers, the odds of LGA increased from 1.56 (overweight, $p<0.001$) to 2.82 (obese Class III, $p<0.001$). The odds of delivering an infant with macrosomia increased with obesity, from 1.49 (overweight, $p<0.001$) to 2.67 (obese Class III, $p<0.001$). The odds of delivering an LGA infant were higher in women with pre-existing diabetes than in those with gestational diabetes (AOR=1.03, $p=0.014$). Compared with women without diabetes, those with pre-existing

Table 1. BMI Status Across Maternal Characteristics Among Singleton Pregnancies From CDC PRAMS, U.S., 2012–2015

Characteristics	Underweight (n=5,670)	Normal (n=61,466)	Overweight (n=31,164)	Obese Class I (n= 16,398)	Obese Class II (n=7,762)	Obese Class III (n= 5,741)	p-Value	Unweighted count
Total, %	4.0 (0.1)	49.1 (0.2)	24.4 (0.2)	12.4 (0.3)	6.0 (0.2)	4.1 (0.1)		128,199
Maternal age, years, %							<0.001	
<25	5.9 (0.2)	49.8 (.5)	22.9 (0.4)	12.0 (0.3)	5.9 (0.2)	3.5 (0.2)		36,791
25–29	4.2 (0.2)	48.5 (0.4)	24.3 (0.3)	12.7 (0.3)	5.9 (0.2)	4.5 (0.2)		36,950
30–34	2.9 (0.1)	50.6 (0.4)	24.9 (0.4)	11.8 (0.3)	5.7 (0.2)	4.1 (0.2)		34,782
35–39	2.8 (0.2)	47.0 (0.6)	26.0 (0.5)	13.5 (0.3)	6.5 (0.3)	4.3 (0.2)		15,950
≥40	1.2 (0.2)	45.1 (1.3)	27.7 (1.2)	14.7 (0.9)	7.2 (0.6)	3.9 (0.4)		3,724
Maternal education, %							<0.001	
<12 years	6.0 (0.3)	44.1 (0.7)	26.2 (0.6)	13.9 (0.5)	5.9 (0.3)	3.9 (0.3)		17,099
12 years	4.7 (0.2)	43.9 (0.5)	24.0 (0.4)	14.7 (0.3)	7.3 (0.3)	5.4 (0.2)		31,842
>12 years	3.4 (0.1)	52.1 (0.3)	24.2 (0.2)	11.3 (0.2)	5.5 (0.1)	3.7 (0.1)		77,857
Marital status, %							<0.001	
Married	3.5 (0.1)	51.9 (0.3)	24.4 (0.2)	11.4 (0.2)	5.3 (0.1)	3.5 (0.1)		75,743
Other ^a	4.9 (0.2)	44.6 (0.4)	24.3 (0.3)	14.0 (0.3)	7.0 (0.2)	5.2 (0.2)		51,948
Parity, %							<0.001	
0	4.7 (0.1)	53.8 (0.3)	21.9 (0.3)	10.7 (0.2)	5.1 (0.1)	3.7 (0.1)		52,884
1	3.8 (0.1)	48.6 (0.4)	25.5 (0.3)	12.5 (0.3)	5.5 (0.2)	4.1 (0.2)		39,506
≥2	3.3 (0.2)	42.4 (0.4)	26.9 (0.4)	14.9 (0.3)	7.8 (0.3)	4.8 (0.2)		34,962
Infertility treatment, %							0.017	
No	4.0 (0.1)	49.0 (0.2)	24.5 (0.2)	12.4 (0.2)	5.9 (0.1)	4.1 (0.1)		104,888
Yes	3.0 (0.5)	51.8 (1.7)	21.3 (1.4)	11.2 (1.0)	7.5 (1.0)	5.2 (0.8)		1,713
First PNC visit, %							<0.001	
First trimester	3.7 (0.1)	49.4 (0.2)	24.5 (0.2)	12.3 (0.2)	6.0 (0.1)	4.1 (0.1)		106,592
After the first trimester	5.3 (0.3)	47.1 (0.7)	24.3 (0.6)	13.2 (0.5)	6.0 (0.4)	4.1 (0.3)		18,016
No PNC visits	8.2 (2.5)	49.3 (2.9)	22.2 (2.1)	10.0 (1.7)	4.1 (0.9)	6.1 (1.3)		1,065
Number of PNC visits, %							<0.001	
≤8	5.3 (0.3)	48.2 (0.6)	24.3 (0.5)	12.0 (0.4)	6.2 (0.3)	3.9 (0.2)		26,569
9–11	4.1 (0.2)	50.8 (0.4)	23.7 (0.3)	12.2 (0.3)	5.5 (0.2)	3.6 (0.2)		39,090
≥12	3.5 (0.1)	48.4 (0.3)	24.8 (0.3)	12.7 (0.2)	6.2 (0.2)	4.5 (0.1)		57,962
Payment at delivery, Medicaid, %							<0.001	
No	3.7 (0.1)	50.9 (0.3)	24.3 (0.2)	11.9 (0.2)	5.5 (0.1)	3.6 (0.1)		95,380
Yes	5.0 (0.2)	42.7 (0.5)	24.6 (0.4)	14.2 (0.3)	7.6 (0.3)	5.9 (0.2)		32,600
Gestational weight gain (mean, SE), LB ^b	30.2 (0.3)	32.3 (0.1)	31.0 (0.1)	27.1 (0.2)	23.7 (0.3)	20.1 (0.4)	<0.001	123,278
Diabetes status, %							<0.001	
Nondiabetic	4.1 (0.1)	50.6 (0.2)	24.3 (0.2)	11.8 (0.1)	5.5 (0.1)	3.7 (0.1)		117,472
PD	3.3 (0.5)	36.7 (1.4)	24.0 (1.3)	17.8 (1.1)	9.2 (0.8)	9.0 (0.9)		3,094
GDM	2.3 (0.3)	29.0 (0.8)	25.6 (0.8)	21.2 (0.8)	12.1 (0.6)	9.7 (0.6)		7,633

Note: All reported percentages (SE) are weighted and design corrected. Each row is a category for participants' characteristics. The second to the seventh columns are the proportions for each BMI level in the category for the row. The eighth column gives *p*-values for chi-square (the design-based test values were used) between BMI levels and other characteristics. The last column shows the number of subjects in the category for each row.

^aAsian, American Indian/Alaska Native, Pacific Islander, or multiple.

^bThe *p*-value for gestational weight gain was based on adjusted Wald test.

CDC, Centers for Disease Control and Prevention; GDM, gestational diabetes mellitus; lb, pound; PD, pre-existing diabetes; PNC, prenatal care; PRAMS, Pregnancy Risk Assessment Monitoring System.

diabetes had increased odds of delivering large infants (LGA: AOR=1.88, *p*<0.001; macrosomic: AOR=1.47, *p*=0.018). Likewise, compared with women without diabetes, women with gestational diabetes had increased odds of delivering large infants (LGA: AOR=1.49, *p*<0.001). Other independent predictors for delivering an LGA infant included maternal age (*p*<0.001), maternal

ethnicity/race (*p*=0.001), parity (*p*<0.001), gestational weight gain (*p*<0.001), and male sex of the infant. Independent predictors for delivering an infant with macrosomia were maternal ethnicity/race (*p*=0.001), parity (*p*<0.001), gestational weight gain (*p*<0.001), and male sex of the infant (*p*<0.001). The interaction of obesity and diabetes on the odds of LGA or macrosomia was

Table 2. LGA and Macrosomia in Newborn Infants by Maternal and Infant Characteristics Among Singleton Pregnancies From CDC PRAMS, 2012–2015

Characteristics	LGA (>90th percentile)			Macrosomia (birthweight >4,000 g)		
	No (n=115,696)	Yes (n=12,503)	p-Value	No (n=117,184)	Yes (n=11,015)	p-Value
%	90.0 (0.1)	10.0 (0.1)		91.1 (0.1)	8.9 (0.1)	
Maternal age, %			<0.001			<0.001
<25	92.9 (0.3)	7.1 (0.3)		93.6 (0.2)	6.4 (0.2)	
25–29	90.4 (0.2)	9.6 (0.2)		91.3 (0.2)	8.7 (0.2)	
30–34	88.4 (0.3)	11.6 (0.2)		89.4 (0.2)	10.6 (0.2)	
35–39	87.5 (0.4)	12.5 (0.4)		89.4 (0.4)	10.6 (0.4)	
≥40	87.1 (0.8)	12.9 (0.8)		90.4 (0.7)	9.6 (0.7)	
Maternal education, %			<0.001			<0.001
<12	91.4 (0.4)	8.6 (0.4)		93.2 (0.4)	6.8 (0.4)	
12	91.1 (0.3)	8.9 (0.3)		92.4 (0.3)	7.6 (0.3)	
≥12	89.4 (0.2)	10.6 (0.2)		90.3 (0.2)	9.7 (0.2)	
Marital status, %						
Married	89.2 (0.2)	10.8 (0.2)	<0.001	90.0 (0.2)	10.0 (0.2)	<0.001
Other	91.3 (0.2)	8.7 (0.2)		93.0 (0.2)	7.0 (0.2)	
Parity, %			<0.001			<0.001
0	92.8 (0.2)	7.2 (0.2)		92.7 (0.2)	7.3 (0.2)	
1	88.8 (0.2)	11.2 (0.2)		90.6 (0.2)	9.4 (0.2)	
≥2	87.3 (0.3)	12.7 (0.3)		89.3 (0.3)	10.7 (0.3)	
Infertility treatment, %			0.679			0.298
No	90.1 (0.1)	9.9 (0.1)		91.2 (0.1)	8.8 (0.1)	
Yes	89.6 (1.1)	10.4 (1.1)		90.1 (1.0)	9.9 (1.0)	
First PNC visit, %			0.012			0.008
First trimester	89.8 (0.1)	10.2 (0.1)		90.9 (0.1)	9.1 (0.1)	
After the first trimester	91.1 (0.4)	8.9 (0.4)		92.1 (0.4)	7.9 (0.4)	
No PNC visits	90.4 (1.5)	9.6 (1.5)		93.1 (1.4)	6.9 (1.4)	
Number of PNC visits, %			<0.001			<0.001
≤8	91.3 (0.3)	8.7 (0.3)		93.5 (0.3)	6.5 (0.3)	
9–11	90.7 (0.2)	9.3 (0.2)		92.3 (0.2)	7.7 (0.2)	
≥12	89.1 (0.2)	10.9 (0.2)		89.5 (0.2)	10.5 (0.2)	
Payment at delivery, Medicaid, %			0.002			<0.001
No	89.8 (0.2)	10.2 (0.2)		90.6 (0.1)	9.4 (0.1)	
Yes	90.8 (0.3)	9.2 (0.3)		93.0 (0.2)	7.0 (0.2)	
Sex, %			0.180			<0.001
Male	90.2 (0.2)	9.8 (0.2)		89.0 (0.2)	11.0 (0.2)	
Female	89.8 (0.2)	10.2 (0.2)		93.4 (0.2)	6.6 (0.2)	

All reported percentages are weighted and design corrected. Each row is a category for a characteristic. The second and third columns are the proportions for LGA category for the row. The fifth and sixth columns are the proportions for macrosomia. The fourth and seventh columns give p-values for chi-square (the design-based p-values were used) between LGA and macrosomia levels and other characteristics, respectively. LGA is defined as >90th percentile birthweight for gestational age, race, and fetal sex.

CDC, Centers for Disease Control and Prevention; LGA, large for gestational age; PNC, prenatal care; PRAMS, Pregnancy Risk Assessment Monitoring System.

significant only for the morbidly obese category (LGA: OR=2.15, p=0.001; macrosomia: OR=2.06, p=0.008).

DISCUSSION

In this large population-based study of pregnancy and prepregnancy health surveillance data, we evaluated the

combined effect of maternal obesity and diabetes (pre-existing or gestational diabetes) on the risk of having an LGA infant or an infant with macrosomia. We found that the proportion of women with pre-existing and gestational diabetes increased with the degree of obesity. Maternal obesity and pre-existing and gestational diabetes were strong predictors of delivering an LGA infant or an infant with macrosomia. Obesity and diabetes had an

Table 3. Weighted Prevalence (%) of LGA and Macrosomia by BMI and Diabetes Status Among Singleton Pregnancies From CDC PRAMS, 2012–2015

Characteristics	LGA (>90th percentile), mean (SE)	Macrosomia (birthweight >4,000 g), mean (SE)	Unweighted count <i>n</i>
BMI			
Underweight (<18.5)	3.7 (0.4)	3.2 (0.4)	5,670
Normal weight (18.5–24.9)	7.5 (0.2)	7.3 (0.2)	61,466
Overweight (25.0–29.9)	11.6 (0.3)	10.1 (0.3)	31,164
Class 1 obesity (30.0–34.9)	13.6 (0.4)	11.3 (0.4)	16,396
Class 2 obesity (35.0–39.9)	15.7 (0.8)	12.1 (0.7)	7,762
Class 3 obesity (≥40.0)	16.9 (0.8)	13.5 (0.8)	5,741
Diabetes status			
Nondiabetic	9.3 (0.1)	8.6 (0.1)	117,472
PD	19.9 (1.3)	12.6 (0.9)	3,094
GDM	17.6 (0.1)	12.2 (0.6)	7,633

Note: Values are weighted percentages (95% CI) and took into account the design effect.

CDC, Centers for Disease Control and Prevention; GDM, gestational diabetes mellitus; LGA, large for gestational age; PD, pre-existing diabetes; PRAMS, Pregnancy Risk Assessment Monitoring System.

additive effect on the odds of delivering LGA infants or infants with macrosomia.

In a recent study using U.S. natality data covering the period 1971–2017, the incidence of macrosomia varied considerably depending on the cut off birthweight used to classify birthweight.³² The authors reported 8.14% (Grade 1 macrosomia: birthweight=4,000–4,499 g), 1.32% (Grade 2 macrosomia: birthweight=4,500–4,999 g), and 0.16% (Grade 3 macrosomia≥5,000 g). These estimates are consistent with the findings from our study. Therefore, the estimated proportion of macrosomia in the population could vary considerably on the basis of the cut off (e.g., >4,000 g vs 4,500 g) used to define the infant weight status. Although previous studies have shown that maternal obesity and gestational diabetes were associated with an increased risk of having an LGA infant or an infant with macrosomia,^{26,33–40} data on the combined effect are limited. This study provided evidence of the combined effects of maternal obesity and pre-existing and gestational diabetes on the odds of having an LGA infant and an infant with macrosomia. Furthermore, although previous studies often focus on either pre-existing diabetes or gestational diabetes, we simultaneously compared LGA and macrosomia across different BMI categories, including the degree of adiposity by diabetes types, providing stronger evidence than what is reported in most studies. Our results showed that the risk for both LGA and macrosomia increased with the degree of adiposity (obesity grade). The risk of LGA and macrosomia were higher for mothers with pre-existing and gestational diabetes than for those without diabetes. Our results show that the risk of having an LGA infant and an infant with

macrosomia was remarkably higher in women with morbid obesity (BMI=40+) with either pre-existing or gestational diabetes. Overall, the result showed that morbid obesity poses a higher risk for LGA and macrosomia than pre-existing or gestational diabetes alone. Because obesity is directly associated with a dysregulation in glucose metabolism (and exacerbated during pregnancy), this may explain why women with morbid obesity with diabetes were more likely to have LGA infants and infants with macrosomia than those with either condition alone (i.e., women with obesity without diabetes or normal weight women with diabetes).

Mechanistically, women with diabetes are more likely to have large babies because of the abnormally higher glucose concentration available to the fetus. In gestational diabetes, there is poor maternal glucose utilization, leading to more glucose crossing the placenta into the fetal circulation.⁴¹ Fetal hyperinsulinemia occurs to correct the high glucose concentration by stimulating excessive fetal anabolism and growth.^{26,42} It appears that the effects of maternal gestational diabetes continue to have a negative impact beyond infancy. For instance, it has been shown that infants born to mothers with gestational diabetes are at an increased risk of becoming obese at a younger age (adolescent) and are more likely to develop Type II diabetes in later life—creating a vicious cycle of diabetes.⁴³ Thus, maternal diabetes during pregnancy can lead to transgenerational transmission of diabetes risk.²⁶ A classic example of intergeneration transmission of birthweight has been illustrated by a strong correlation between birthweights of grandmothers and their granddaughters on the basis of large hospital

Table 4. Association Between BMI and Diabetes Status With LGA and Macrosomia Among Singleton Pregnancies From CDC PRAMS, 2012–2015

Characteristics	LGA		Macrosomia (birthweight >4,000 g)	
	OR (95% CI)	AOR (95% CI) ^a	OR (95% CI)	AOR (95% CI) ^a
BMI				
Underweight (<18.5)	0.47 (0.37, 0.61) ^{***}	0.54 (0.42, 0.70) ^{***}	0.41 (0.32, 0.53) ^{**}	0.53(0.41,0.68) ^{**}
Normal weight (18.5–24.9)	ref	ref	ref	ref
Overweight (25.0–29.9)	1.61 (1.50, 1.73) ^{***}	1.56 (1.44, 1.70) ^{***}	1.42 (1.32, 1.53) ^{***}	1.49 (1.37, 1.62) ^{***}
Class 1 obesity (30.0–34.9)	1.94 (1.79, 2.12) ^{***}	2.01 (1.82, 2.22) ^{***}	1.62 (1.48, 1.77) ^{***}	1.88 (1.69, 2.08) ^{***}
Class 2 obesity (35.0–39.9)	2.29 (2.03, 2.58) ^{***}	2.61 (2.24, 3.05) ^{***}	1.75 (1.52, 2.01) ^{***}	2.28 (1.91, 2.72) ^{***}
Class 3 obesity (≥40.0)	2.51 (2.21, 2.85) ^{***}	2.82 (2.42, 3.29) ^{***}	1.99 (1.73, 2.29) ^{***}	2.67 (2.27, 3.14) ^{***}
Diabetes status				
Nondiabetic	ref	ref	ref	ref
PD	2.43 (2.07, 2.86) ^{***}	1.88 (1.41, 2.50) ^{***}	1.54 (1.30, 1.82) ^{***}	1.47 (1.07, 2.01) [*]
GDM	2.09 (1.88, 2.32) ^{***}	1.49 (1.20, 1.86) ^{***}	1.49 (1.32, 1.68) ^{***}	1.10 (0.85, 1.41)
BMI and diabetes interaction				
Normal weight nondiabetic	—	ref	—	ref
Underweight # PD	—	0.69 (0.17, 2.86)	—	1.27 (0.34, 4.67)
Underweight # GDM	—	1.89 (0.55, 6.45)	—	0.94 (0.16, 5.43)
Overweight # PG	—	1.15 (0.64, 2.05)	—	0.79 (0.48, 1.29)
Overweight # GDM	—	0.94 (0.69, 1.28)	—	0.99 (0.69, 1.42)
Class 1 obesity # PD	—	1.51 (0.96, 2.38)	—	1.14 (0.68, 1.92)
Class 1 obesity # GDM	—	1.13 (0.82, 1.55)	—	1.30 (0.90, 1.87)
Class 2 obesity # PD	—	1.36 (0.78, 2.37)	—	1.14 (0.59, 2.23)
Class 2 obesity # GDM	—	1.21 (0.83, 1.77)	—	1.18 (0.76, 1.84)
Class 3 obesity # PG	—	1.41 (0.80, 2.48)	—	1.40 (0.75, 2.61)
Class 3 obesity # GDM	—	2.15 (1.36, 3.40) ^{**}	—	2.06 (1.21, 3.54) ^{**}

Note: Boldface indicates statistical significance (**p*<0.05, ***p*<0.01, and ****p*<0.001).

^aLogistic regression adjusted for maternal age (<25, 25–29, 30–34, 35–39, and ≥40 years), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, other [Asian, American Indian/Alaska Native, Pacific Islander, or multiple]), mother’s education (<12, 12, or ≥12 years), marital status (married or not married), parity (0, 1, or ≥2), initiation of prenatal care (first trimester, after first trimester [late], or not at all), health insurance, number of prenatal care visits, gestational weight gain, and newborn sex.

CDC, Centers for Disease Control and Prevention; GDM, gestational diabetes mellitus; LGA, large for gestational age; PD, pre-existing diabetes; PRAMS, Pregnancy Risk Assessment Monitoring System.

records from Aberdeen Maternity and Neonatal Data-bank in the United Kingdom.⁴⁴

These findings show the importance of maternal weight before pregnancy on fetal outcomes and suggest that both obesity and diabetes before and during pregnancy should be of public health interest to increase the chance of optimal birth weight. The results of this work have significance in terms of providing education to women with obesity or diabetes who are planning to become pregnant. Many women are unaware of diabetes status in the preconception phase,⁴⁵ and many pregnancies are unplanned/unintended,⁴⁶ and because obesity develops over the years and it is difficult to lose weight, it is important to start targeting young women with messages about the importance of a healthy lifestyle and nutrition targeted to maintaining a healthy weight, particularly in underserved populations where the prevalence of both obesity and diabetes tend to be high but

access to health care is poor. Currently, obstetrician-gynecologists provide educational materials to patients with prepregnancy BMI in the overweight/obese ranges. Those with pre-existing diabetes are immediately identified as likely requiring additional clinical management. However, women with the highest risk of adverse pregnancy outcomes are patients with reduced ability to access antenatal care services because of a constellation of mitigating factors.⁴⁷ If women are provided increased access to health care and screening for diabetes in adolescents and young women, it would improve their ability to appropriately manage conditions such as diabetes and obesity in pregnancy and help to improve birth outcomes, including birthweights. With increased health-care access to adolescent and young women in underserved populations, they would seek specialist care early as they prepare to conceive and the best prenatal care to optimize fetal growth. Furthermore, as maternal

age for first-time pregnancy continues to rise in the U.S.,^{48,49} early counseling, including diabetes education for women planning to conceive, will be important for early detection of pre-existing diabetes and gestational diabetes to optimize maternal diet and care to improve birth outcomes, including birthweight.

Blood glucose management during pregnancy improves pregnancy outcomes in patients with gestational diabetes, but the extent to which the length (time since diagnosis) of pre-existing diabetes contributes to excessive fetal growth is unknown. Studies, particularly among underserved populations, are needed to evaluate the effect of the duration of pre-existing diabetes on excessive fetal growth. Given that most fetal growth occurs during the third trimester, it will be interesting to study the effect of strict maternal blood glucose regulation on excessive fetal growth stratified by maternal age, BMI, and race, which are all associated with fetal birth weight.

Limitations

Data for BMI were based on self-reported weight and height. LGA and macrosomia were based on actual birthweight from birth certificate data. Although there may be some concerns about self-reported weight and height, previous studies comparing self-reported with measured height accuracy suggest that measurements were comparable and provide a reliable proxy measure across sex and race/ethnicity.^{50–53}

CONCLUSIONS

In conclusion, this study showed that the risk of both LGA and macrosomia increases with maternal prepregnancy BMI irrespective of maternal diabetes status. Pre-existing diabetes poses a higher risk of delivering large babies than gestational diabetes. Women who are morbidly obese (BMI of ≥ 40 kg/m²) with diabetes are particularly at severe risk for delivering LGA infants and infants with macrosomia.

ACKNOWLEDGMENTS

The authors would like to thank The Pregnancy Risk Assessment Monitoring System Working Group—Danita Crear (Alabama); Kathy Perham-Hester (Alaska); Mary McGehee (Arkansas); Alyson Shupe (Colorado); Jennifer Morin (Connecticut); George Yocher, MS (Delaware); Jerri Foreman (Florida); Jenna Self (Georgia); Emily Roberson (Hawaii); Theresa Sandidge (Illinois); Jenny Durica (Indiana); Sarah Mauch (Iowa); Jane Herwehe (Louisiana); Tom Patenaude (Maine); Diana Cheng (Maryland); Emily Lu (Massachusetts); Cristin Larder (Michigan); Judy Punnyko (Minnesota); Brenda Hughes (Mississippi); Venkata Garikapaty, MSc, MS, PhD, MPH (Missouri); JoAnn Dotson (Montana); Brenda Coufal (Nebraska); Paulette

Valliere (New Hampshire); Lakota Kruse, MD (New Jersey); Eirian Coronado (New Mexico); Anne Radigan-Garcia (New York State); Candace Mulready-Ward (New York City); Kathleen Jones-Vessey (North Carolina); Sandra Anseth (North Dakota); Connie Geidenberger, PhD (Ohio); Alicia Lincoln (Oklahoma); Kenneth Rosenberg (Oregon); Tony Norwood (Pennsylvania); Sam Viner-Brown (Rhode Island); Mike Smith, MSPH (South Carolina); Rochelle Kingsley (Texas); Angela Miller (Tennessee); Tanya Guthrie (Texas); Lynsey Gammon (Utah); Peggy Brozicevic (Vermont); Marilyn Wenner (Virginia); Linda Lohdefinck (Washington); Melissa Baker (West Virginia); Mireille Perzan, MPH (Wisconsin); and Amy Spieker (Wyoming)—and the Centers for Disease Control and Prevention Pregnancy Risk Assessment Monitoring System Team, Applied Sciences Branch, Division of Reproductive Health. Deidentified individual participant data will not be made available.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

This work has not been presented or published elsewhere.

Declarations of interest: none.

CREDIT AUTHOR STATEMENT

Sixtus Aguree: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft. Xiaofei Zhang: Formal analysis, Validation, Writing – review & editing. Manju B. Reddy: Conceptualization, Investigation, Methodology, Supervision, Writing – review & editing.

SUPPLEMENTARY MATERIALS

Supplementary material associated with this article can be found in the online version at [doi:10.1016/j.focus.2023.100071](https://doi.org/10.1016/j.focus.2023.100071).

REFERENCES

- Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. *NCHS Data Brief*. 2020;360:1–8. <https://pubmed.ncbi.nlm.nih.gov/32487284/>. Accessed October 21, 2021.
- Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level prevalence of adult obesity and severe obesity. *N Engl J Med*. 2019;381(25):2440–2450. <https://doi.org/10.1056/NEJMsa1909301>.
- Riaz H, Khan MS, Siddiqi TJ, et al. Association between obesity and cardiovascular outcomes: a systematic review and meta-analysis of Mendelian randomization studies. *JAMA Netw Open*. 2018;1(7):e183788. <https://doi.org/10.1001/jamanetworkopen.2018.3788>.
- Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2016;23(9):956–966. <https://doi.org/10.1177/2047487315623884>.
- Eckel RH, Barouch WW, Ershov AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. *Circulation*. 2002;105(24):2923–2928. <https://doi.org/10.1161/01.cir.0000017823.53114.4c>.

6. Chu SY, Callaghan WM, Kim SY, et al. Maternal obesity and risk of gestational diabetes mellitus. *Diabetes Care*. 2007;30(8):2070–2076. <https://doi.org/10.2337/dc06-2559a>.
7. Huet J, Beucher G, Rod A, Morello R, Dreyfus M. Joint impact of gestational diabetes and obesity on perinatal outcomes. *J Gynecol Obstet Hum Reprod*. 2018;47(9):469–476. <https://doi.org/10.1016/j.jogoh.2018.08.003>.
8. Ehrenberg HM, Durnwald CP, Catalano P, Mercer BM. The influence of obesity and diabetes on the risk of cesarean delivery. *Am J Obstet Gynecol*. 2004;191(3):969–974. <https://doi.org/10.1016/j.ajog.2004.06.057>.
9. Brown J, Alwan NA, West J, et al. Lifestyle interventions for the treatment of women with gestational diabetes. *Cochrane Database Syst Rev*. 2017;5(5):CD011970. <https://doi.org/10.1002/14651858.CD011970.pub2>.
10. Kim C, Berger DK, Chamany S. Recurrence of gestational diabetes mellitus: a systematic review. *Diabetes Care*. 2007;30(5):1314–1319. <https://doi.org/10.2337/dc06-2517>.
11. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. *Diabetes Care*. 2002;25(10):1862–1868. <https://doi.org/10.2337/diacare.25.10.1862>.
12. Bowers K, Laughon SK, Kiely M, Brite J, Chen Z, Zhang C. Gestational diabetes, pre-pregnancy obesity and pregnancy weight gain in relation to excess fetal growth: variations by race/ethnicity. *Diabetologia*. 2013;56(6):1263–1271. <https://doi.org/10.1007/s00125-013-2881-5>.
13. Rosenberg TJ, Garbers S, Lipkind H, Chiasson MA. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups. *Am J Public Health*. 2005;95(9):1545–1551. <https://doi.org/10.2105/AJPH.2005.065680>.
14. Simmons D. Diabetes and obesity in pregnancy. *Best Pract Res Clin Obstet Gynaecol*. 2011;25(1):25–36. <https://doi.org/10.1016/j.bpobgyn.2010.10.006>.
15. Chatfield J. ACOG issues guidelines on fetal macrosomia. *American College of Obstetricians and Gynecologists. Am Fam Physician*. 2001;64(1):169–170.
16. Abramowicz JS, Ahn JT. Fetal macrosomia. Waltham, MA: UpToDate <https://www.uptodate.com/contents/fetal-macrosomia>. Accessed September 18, 2022.
17. Beta J, Khan N, Khalil A, Fiolna M, Ramadan G, Akolekar R. Maternal and neonatal complications of fetal macrosomia: systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2019;54(3):308–318. <https://doi.org/10.1002/uog.20279>.
18. Ogonowski J, Miazgowski T. Intergenerational transmission of macrosomia in women with gestational diabetes and normal glucose tolerance. *Eur J Obstet Gynecol Reprod Biol*. 2015;195:113–116. <https://doi.org/10.1016/j.ejogrb.2015.10.002>.
19. Ikedionwu CA, Dongarwar D, Yusuf KK, Ibrahim S, Salinas-Miranda AA, Salihi HM. Pre-pregnancy maternal obesity, macrosomia, and risk of stillbirth: a population-based study. *Eur J Obstet Gynecol Reprod Biol*. 2020;252:1–6. <https://doi.org/10.1016/j.ejogrb.2020.06.004>.
20. Salihi HM, Dongarwar D, King LM, Yusuf KK, Ibrahim S, Salinas-Miranda AA. Phenotypes of fetal macrosomia and risk of stillbirth among term deliveries over the previous four decades. *Birth*. 2020;47(2):202–210. <https://doi.org/10.1111/birt.12479>.
21. Sparano S, Ahrens W, De Henaau S, et al. Being macrosomic at birth is an independent predictor of overweight in children: results from the IDEFICS study. *Matern Child Health J*. 2013;17(8):1373–1381. <https://doi.org/10.1007/s10995-012-1136-2>.
22. Yogev Y, Langer O. Pregnancy outcome in obese and morbidly obese gestational diabetic women. *Eur J Obstet Gynecol Reprod Biol*. 2008;137(1):21–26. <https://doi.org/10.1016/j.ejogrb.2007.03.022>.
23. Catalano PM, McIntyre HD, Cruickshank JK, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. *Diabetes Care*. 2012;35(4):780–786. <https://doi.org/10.2337/dc11-1790>.
24. Fong A, Serra A, Herrero T, Pan D, Ogunyemi D. Pre-gestational versus gestational diabetes: a population based study on clinical and demographic differences. *J Diabetes Complications*. 2014;28(1):29–34. <https://doi.org/10.1016/j.jdiacomp.2013.08.009>.
25. Ehrenberg HM, Mercer BM, Catalano PM. The influence of obesity and diabetes on the prevalence of macrosomia. *Am J Obstet Gynecol*. 2004;191(3):964–968. <https://doi.org/10.1016/j.ajog.2004.05.052>.
26. Kc K, Shakya S, Zhang H. Gestational diabetes mellitus and macrosomia: a literature review. *Ann Nutr Metab*. 2015;66(suppl 2):14–20. <https://doi.org/10.1159/000371628>.
27. CDC PRAMS. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. <https://www.cdc.gov/prams/index.htm>. Updated May 23, 2022. Accessed April 11, 2021.
28. Gilbert BC, Shulman HB, Fischer LA, Rogers MM. The Pregnancy Risk Assessment Monitoring System (PRAMS): methods and 1996 response rates from 11 states. *Matern Child Health J*. 1999;3(4):199–209. <https://doi.org/10.1023/a:1022325421844>.
29. Shulman HB, D'Angelo DV, Harrison L, Smith RA, Warner L. The Pregnancy Risk Assessment Monitoring System (PRAMS): overview of design and methodology. *Am J Public Health*. 2018;108(10):1305–1313. <https://doi.org/10.2105/AJPH.2018.304563>.
30. WHO. Physical status: the use of and interpretation of anthropometry, report of a WHO expert committee. Geneva, Switzerland: WHO. <https://apps.who.int/iris/handle/10665/37003>. Published 1995. Accessed June 20, 2016.
31. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. *Am J Clin Nutr*. 1998;68(4):899–917. <https://doi.org/10.1093/ajcn/68.4.899>.
32. Salihi HM, Dongarwar D, King LM, Yusuf KK, Ibrahim S, Salinas-Miranda AA. Trends in the incidence of fetal macrosomia and its phenotypes in the United States, 1971–2017. *Arch Gynecol Obstet*. 2020;301(2):415–426. <https://doi.org/10.1007/s00404-019-05400-9>.
33. Riskin A, Itzhaki O, Bader D, Iofe A, Toropine A, Riskin-Mashiah S. Perinatal outcomes in infants of mothers with diabetes in pregnancy. *Isr Med Assoc J*. 2020;22(9):569–575. <https://pubmed.ncbi.nlm.nih.gov/33236556/>. Accessed June 18, 2021.
34. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med*. 2008;358(19):1991–2002. <https://doi.org/10.1056/NEJMoa0707943>.
35. Machado C, Monteiro S, Oliveira MJ, Grupo de Estudo de Diabetes e Gravidez da Sociedade Portuguesa de Diabetologia. Impact of overweight and obesity on pregnancy outcomes in women with gestational diabetes - results from a retrospective multicenter study. *Arch Endocrinol Metab*. 2020;64(1):45–51. <https://doi.org/10.20945/2359-399700000178>.
36. Åmark H, Westgren M, Persson M. Prediction of large-for-gestational-age infants in pregnancies complicated by obesity: a population-based cohort study. *Acta Obstet Gynecol Scand*. 2019;98(6):769–776. <https://doi.org/10.1111/aogs.13546>.
37. Wang N, Song L, Sun B, et al. Contribution of gestational diabetes mellitus heterogeneity and prepregnancy body mass index to large-for-gestational-age infants—a retrospective case-control study. *J Diabetes*. 2021;13(4):307–317. <https://doi.org/10.1111/1753-0407.13113>.
38. Neal K, Ullah S, Glastras SJ. Obesity class impacts adverse maternal and neonatal outcomes independent of diabetes. *Front Endocrinol (Lausanne)*. 2022;13:832678. <https://doi.org/10.3389/fendo.2022.832678>.
39. Zong X, Wang H, Yang L, et al. Maternal pre-pregnancy body mass index categories and infant birth outcomes: a population-based study of 9 million mother–infant pairs. *Front Nutr*. 2022;9:789833. <https://doi.org/10.3389/fnut.2022.789833>.

40. Gaudet L, Ferraro ZM, Wen SW, Walker M. Maternal obesity and occurrence of fetal macrosomia: a systematic review and meta-analysis. *BioMed Res Int*. 2014;2014:640291. <https://doi.org/10.1155/2014/640291>.
41. Catalano PM. Obesity, insulin resistance, and pregnancy outcome. *Reproduction*. 2010;140(3):365–371. <https://doi.org/10.1530/REP-10-0088>.
42. Ornoy A, Becker M, Weinstein-Fudim L, Ergaz Z. Diabetes during pregnancy: a maternal disease complicating the course of pregnancy with long-term deleterious effects on the offspring. A clinical review. *Int J Mol Sci*. 2021;22(6):2965. <https://doi.org/10.3390/ijms22062965>.
43. EU Alejandro, Mamerto TP, Chung G, et al. Gestational diabetes mellitus: a harbinger of the vicious cycle of diabetes. *Int J Mol Sci*. 2020;21(14):5003. <https://doi.org/10.3390/ijms21145003>.
44. Lahti-Pulkkinen M, Bhattacharya S, Rääkkönen K, Osmond C, Norman JE, Reynolds RM. Intergenerational transmission of birth weight across 3 generations. *Am J Epidemiol*. 2018;187(6):1165–1173. <https://doi.org/10.1093/aje/kwx340>.
45. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. *Diabetes Res Clin Pract*. 2014;103(2):150–160. <https://doi.org/10.1016/j.diabres.2013.11.001>.
46. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. *N Engl J Med*. 2016;374(9):843–852. <https://doi.org/10.1056/NEJMsa1506575>.
47. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Division of Behavioral and Social Sciences and Education et al., eds. Birth settings in America: outcomes, quality, access, and choice. Washington, DC: National Academies Press (U.S.). <https://www.ncbi.nlm.nih.gov/books/NBK555488/>. Published 2020. Accessed September 18, 2021.
48. Mathews TJ, Hamilton BE. First births to older women continue to rise, *NCHS Data Brief*. 2014;152:1–8. <https://pubmed.ncbi.nlm.nih.gov/24813228/>. Accessed January 10, 2018.
49. Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States: 2000–2014, *NCHS Data Brief*. 2016;232:1–8. <https://pubmed.ncbi.nlm.nih.gov/26828319/>. Accessed January 10, 2018.
50. Pérez A, Gabriel K, Nehme EK, Mandell DJ, Hoelscher DM. Measuring the bias, precision, accuracy, and validity of self-reported height and weight in assessing overweight and obesity status among adolescents using a surveillance system. *Int J Behav Nutr Phys Act*. 2015;12(suppl 1):S2. <https://doi.org/10.1186/1479-5868-12-S1-S2>.
51. Dekkers JC, van Wier MF, Hendriksen IJ, Twisk JW, van Mechelen W. Accuracy of self-reported body weight, height and waist circumference in a Dutch overweight working population. *BMC Med Res Methodol*. 2008;8(1):69. <https://doi.org/10.1186/1471-2288-8-69>.
52. Ross KM, Eastman A, Wing RR. Accuracy of self-report versus objective smart-scale weights during a 12-week weight management intervention. *Obesity (Silver Spring)*. 2019;27(3):385–390. <https://doi.org/10.1002/oby.22400>.
53. Olfert MD, Barr ML, Charlier CM, et al. Self-reported vs. measured height, weight, and BMI in young adults. *Int J Environ Res Public Health*. 2018;15(10):2216. <https://doi.org/10.3390/ijerph15102216>.